Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 1
2005 1
2007 1
2008 1
2009 3
2010 1
2011 2
2017 1
2018 2
2022 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Resistance to CDK4/6 inhibition: Mechanisms and strategies to overcome a therapeutic problem in the treatment of hormone receptor-positive metastatic breast cancer.
Papadimitriou MC, Pazaiti A, Iliakopoulos K, Markouli M, Michalaki V, Papadimitriou CA. Papadimitriou MC, et al. Among authors: pazaiti a. Biochim Biophys Acta Mol Cell Res. 2022 Dec;1869(12):119346. doi: 10.1016/j.bbamcr.2022.119346. Epub 2022 Aug 24. Biochim Biophys Acta Mol Cell Res. 2022. PMID: 36030016 Free article. Review.
Margin-free excision of small solid breast carcinomas using the Intact Breast Lesion Excision System®: is it feasible?
Papapanagiotou IK, Koulocheri D, Kalles V, Liakou P, Michalopoulos NV, Al-Harethee W, Georgiou G, Matiatou M, Nonni A, Pazaiti A, Theodoropoulos GE, Menenakos E, Zografos GC. Papapanagiotou IK, et al. Among authors: pazaiti a. Breast Cancer. 2018 Mar;25(2):134-140. doi: 10.1007/s12282-017-0802-z. Epub 2017 Sep 16. Breast Cancer. 2018. PMID: 28918560
Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study.
Tampaki EC, Tampakis A, Alifieris CE, Krikelis D, Pazaiti A, Kontos M, Trafalis DT. Tampaki EC, et al. Among authors: pazaiti a. Clin Drug Investig. 2018 Jul;38(7):639-648. doi: 10.1007/s40261-018-0655-z. Clin Drug Investig. 2018. PMID: 29744672 Clinical Trial.
12 results